TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death
Related Experiment Video
Updated: Mar 10, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Junwoo Lee1, Sungkwan An1, Yeong Min Choi1,2
1Research Institute for Molecular-Targeted Drugs, Department of Biological Engineering, Konkuk University, Seoul, 05029, Republic of Korea.
Abstract:
Nutlin-3a is a non-genotoxic, p53-activating, MDM2 inhibitor being investigated as an anticancer agent. Although Nutlin-3a selectively antagonizes the ubiquitin E3 ligase activity of MDM2, its efficacy is not entirely regulated by MDM2 levels in cancer cells. Here, we report that the cytotoxic effects of Nutlin-3a are regulated by TRIAD1 via a positive feedback loop with p53. We found that Nutlin-3a enhanced TRIAD1 transcription in a p53-dependent manner. Using in silico analysis and promoter luciferase assays, we demonstrated that p53-mediated transcription of TRIAD1 is mediated by a p53 consensus sequence in the TRIAD1 promoter region. Silencing TRIAD1 expression in wild-type p53 (p53WT ) cancer cells suppressed Nutlin-3a-mediated p53 activation and p53 target gene expression. These effects were enhanced in TRIAD1-overexpressing p53WT cancer cells, but not in p53-deficient cancer cells. Furthermore, TRIAD1 knockdown significantly reduced the growth inhibitory and cytotoxic effects of Nutlin-3a in p53WT cancer cells, as demonstrated by cell viability assays, cell cycle analysis, clonogenic growth, and soft-agar colony forming assays. Together, these data indicate that TRIAD1 regulates Nutlin-3a-mediated p53 activation and the cytotoxic activity of Nutlin-3a. J. Cell. Biochem. 118: 1733-1740, 2017. © 2016 Wiley Periodicals, Inc.
Insights
Nutlin-3a
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nutlin-3a is an MDM2 inhibitor investigated for cancer therapy.
- Its efficacy is not solely dependent on MDM2 levels.
- TRIAD1's role in Nutlin-3a's anticancer effects is unexplored.
Purpose of the Study:
- To investigate the role of TRIAD1 in regulating the anticancer activity of Nutlin-3a.
- To elucidate the mechanism of TRIAD1-mediated regulation of p53 activation by Nutlin-3a.
Main Methods:
- In silico analysis and promoter luciferase assays to study TRIAD1 transcription.
- TRIAD1 silencing and overexpression in cancer cells.
- Cell viability, cell cycle, clonogenic, and soft-agar assays to assess Nutlin-3a's effects.
Main Results:
- Nutlin-3a enhances TRIAD1 transcription in a p53-dependent manner via a p53 consensus sequence.
- TRIAD1 silencing suppresses Nutlin-3a-induced p53 activation and target gene expression.
- TRIAD1 knockdown reduces Nutlin-3a's cytotoxic and growth inhibitory effects in p53 wild-type cells.
Conclusions:
- TRIAD1 acts as a positive regulator of Nutlin-3a-mediated p53 activation.
- TRIAD1 is crucial for the cytotoxic activity of Nutlin-3a in cancer cells.
- This highlights a novel feedback loop involving TRIAD1 and p53 in cancer therapy.
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
DNA Damage can Stall the Cell Cycle

